TY - JOUR
T1 - Polyomavirus-Negative Merkel Cell Carcinoma
T2 - A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection
AU - Moshiri, Ata S.
AU - Doumani, Ryan
AU - Yelistratova, Lola
AU - Blom, Astrid
AU - Lachance, Kristina
AU - Shinohara, Michi M.
AU - Delaney, Martha
AU - Chang, Oliver
AU - McArdle, Susan
AU - Thomas, Hannah
AU - Asgari, Maryam M.
AU - Huang, Meei Li
AU - Schwartz, Stephen M.
AU - Nghiem, Paul
N1 - Publisher Copyright:
© 2016 The Authors
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Previous studies have reached conflicting conclusions regarding the proportion of Merkel cell carcinomas (MCCs) that contain the Merkel cell polyomavirus (MCPyV) and the clinical significance of tumor viral status. To address these controversies, we detected MCPyV large T antigen using immunohistochemistry with two distinct antibodies and MCPyV DNA using quantitative PCR. Tumors were called MCPyV-positive if two or more of these three assays indicated presence of this virus. A total of 53 of 282 (19%) MCC tumors in this cohort were virus-negative using this multimodal system. Immunohistochemistry with the CM2B4 antibody had the best overall performance (sensitivity = 0.882, specificity = 0.943) compared with the multimodal classification. Multivariate analysis including age, sex, and immunosuppression showed that, relative to MCC patients with virus-positive tumors, virus-negative MCC patients had significantly increased risk of disease progression (hazard ratio = 1.77, 95% confidence interval = 1.20–2.62) and death from MCC (hazard ratio = 1.85, 95% confidence interval = 1.19–2.89). We confirm that approximately 20% of MCCs are not driven by MCPyV and that such virus-negative MCCs, which can be quite reliably identified by immunohistochemistry using the CM2B4 antibody alone, represent a more aggressive subtype that warrants closer clinical follow-up.
AB - Previous studies have reached conflicting conclusions regarding the proportion of Merkel cell carcinomas (MCCs) that contain the Merkel cell polyomavirus (MCPyV) and the clinical significance of tumor viral status. To address these controversies, we detected MCPyV large T antigen using immunohistochemistry with two distinct antibodies and MCPyV DNA using quantitative PCR. Tumors were called MCPyV-positive if two or more of these three assays indicated presence of this virus. A total of 53 of 282 (19%) MCC tumors in this cohort were virus-negative using this multimodal system. Immunohistochemistry with the CM2B4 antibody had the best overall performance (sensitivity = 0.882, specificity = 0.943) compared with the multimodal classification. Multivariate analysis including age, sex, and immunosuppression showed that, relative to MCC patients with virus-positive tumors, virus-negative MCC patients had significantly increased risk of disease progression (hazard ratio = 1.77, 95% confidence interval = 1.20–2.62) and death from MCC (hazard ratio = 1.85, 95% confidence interval = 1.19–2.89). We confirm that approximately 20% of MCCs are not driven by MCPyV and that such virus-negative MCCs, which can be quite reliably identified by immunohistochemistry using the CM2B4 antibody alone, represent a more aggressive subtype that warrants closer clinical follow-up.
UR - http://www.scopus.com/inward/record.url?scp=85015886831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015886831&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2016.10.028
DO - 10.1016/j.jid.2016.10.028
M3 - Article
C2 - 27815175
AN - SCOPUS:85015886831
SN - 0022-202X
VL - 137
SP - 819
EP - 827
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 4
ER -